Global facial injectables market was valued at USD 16.1 billion in 2021, and it is expected to reach a value of USD 29.62 billion by 2028, at a CAGR of more than 9.1% over the forecast period (2022–2028).
Westford, USA, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Facial Injectables Market is growing with each passing year, as people become more aware of the benefits these medications can provide. There are number of different types of facial injectables available on the market, each with its own unique benefits. Some of the most popular options include anti-aging injections, skin rejuvenation injections, and filler treatments.
As per SkyQuest findings in the global facial injectables market, most of the people seek out facial injectables treatments for reducing the appearance of wrinkles, reducing the appearance of lines and creases in the skin, increasing skin thickness and making it more elastic. In addition, it was also found that many people who use facial injectables treatments report increased energy levels and improved cosmetic outcomes.
Other options for nonsurgical facial rejuvenation treatments include laser therapy, microcurrent surgery and resurfacing treatments using liquid or gel fillers. However, consumers across the global facial injectables market are preferring facial injectables since they more effective than these other methods and are typically less expensive.
Get sample copy of this report:
https://skyquestt.com/sample-request/facial-injectables-market
SkyQuest has published a report on global facial injectables market. The report would help in identifying consumers base, market dynamics, trends, growth opportunities, competitive landscape, pricing analysis, consumer behavior and their choices, market share analysis, among others.
Botulin Toxin and Dermal Filler Injection are Holding 58% Market Share
As per SkyQuest latest report on global facial injectables market, over 10 million injections of botulinum toxin (Botox) and 3.6 million dermal filler injections were used by the American consumers alone in 2021. It was pegged at around 7.4 million and 2.6 million in 2018, repetitively. The number has increased by around 29% compared to last year. The global consumption of these two minimally invasive facial injectables have grown 3 times in the last 10 years thanks to rapidly growing awareness among consumers, desire to look good, growing influence of social media, and increasing desire to look like celebrities, among others. This has flourished the consumption of these two facial injectables significantly in the last few years. Demand for botulin toxin and dermal filler is expected to grow at a CAGR of 11.2% in the global facial injectables market. This is due in part to the increasing prevalence of neurological disorders, as well as the growing demand for anti-aging treatments
Injectable botulinum toxin (BOT) and fillers are being prescribed more frequently in the global facial injectables market as they offer more benefits over nonsurgical treatment options such as in reducing wrinkles and sagging skin. The beauty industry is witnessing higher demand for these injectables due to increasing awareness about the aesthetics of these treatments. Furthermore, newer injectable products are gaining popularity owing to their enhanced performance in various treatment conditions such as neck volume restoration, cleft lip correction, etc.
SkyQuest Survey Reveals 37% Americans Tried Facial Injectables, and Number is likely to Surpass 53% by 2030
Nearly 40% of Americans have tried at least one facial injectable, such as Botox and Fillers in the past one year, according to a new survey. Botox (56%) and filler (24%) were the most popular types of injectables sampled in the surveying.
Interestingly, women (62%) are somewhat more likely than men (38%) to have tried a facial injectable in the past year in the facial injectables market. And those who have a college degree or more education (47% vs. 43%) are also more likely to have tried an injectable facial treatment. Most of the consumers are turning to injectables to achieve a more youthful appearance. Either way, this bodes well for the industry as treatments like Botox and fillers continue to gain popularity.
Other popular treatments include glycoprotein type A pegylated liberator injections (Graftobian), Xeomin, and cBotox. Interestingly, men and women have similar preferences when it comes to which injectable treatments, they are interested in.
Browse summary of the report and Complete Table of Contents (ToC):
https://skyquestt.com/report/facial-injectables-market
BOTOX®, including Dysport® and Xeomin® are Go to Product for Facial Injectables
BOTOX®, including Dysport® and Xeomin®, are the top choices in the global facial injectables market. These products are used to treat a variety of facial concerns, including wrinkles, nasolabial folds (smile lines below the nose), improve facial symmetry, eliminate blemishes, and lines from the forehead to the chin.
BOTOX is a topically-applied neurotoxin produced by the bacterium Clostridium botulinum. Dysport® is a botulinum toxin type A (BTX-A) formulation and Xeomin® is a botulinum toxin type B (BTX-B) formulation. As per SkyQuest analysis, Botox by Allergan is holding more than 47% of the global facial injectables market. The product is gaining more popularity than its counterparts despite its higher price. For instance, it costs around $500 per treatment across the US, but the Xeomin and Dysport cost less than $400. On the other hand, dermal fillers often cost between $500-$900 per syringe. Hyaluronic acid (HA) fillers such as JUVÉDERM® and Restylane® on average can cost close to $700 per syringe.
Botulinumtoxin treatments are becoming increasingly popular for facelift patients because they cause very little pain and downtime, and provide long-term results. Dysport® has been especially well-received because it produces minimal side effects and can be administered multiple times per year for best results. Xeomin®, on the other hand, is less popular but offers similar benefits as Dysport®, including reduced wrinkles and smoother skin.
SkyQuest has done a detailed study on global facial injectables market and published a report. The report would help the market players in identifying key growth areas, key insights about consumer behavior, spending capacity, brand preferences, global consumption of facial injectables by value and volume, pricing analysis by region, inflow and outflow of cosmetic tourism, among others.
Speak to Analyst for your custom requirements:
https://skyquestt.com/speak-with-analyst/facial-injectables-market
Top Players in Global Facial Injectables Market
BIOPLUS CO., LTD. (South Korea)
Related Reports in SkyQuest’s Library:
SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.
Email: sales@skyquestt.com
LinkedIn Facebook Twitter
In closing arguments, a federal judge questioned the government’s effort to block the health insurer’s $13 billion acquisition of health-technology firm Change Healthcare.
(Bloomberg) -- For early backers, they’ve been some of the most profitable Chinese stock investments of all time: Tencent Holdings Ltd., Alibaba Group Holding Ltd. and BYD Co.But now big-name investors who’ve made billions from these shares are taking money off the table, underscoring growing angst over the prospects for China’s biggest companies as President Xi Jinping tightens the government’s grip on the private sector and the economy falters under persistent Covid lockdowns.In the latest dev
Instead of trying to understand what the European Central Bank's 'Governing Council' is trying to accomplish, I'm joining the 'Evil Empire' of leveraged-short ETFs.
Advanced Micro Devices stock has risen on expectations for continued market share gains in processors for PCs and servers. After a pullback in its shares, is AMD stock a buy right now?
FuelCell Energy (FCEL) posts wider-than-expected fiscal Q3 loss. FCEL's backlog remains strong and the company continues to deliver modules and meet customer needs through clean energy generation.
Shares of Plug Power Inc. climbed 3.1% in afternoon trading Thursday, in the wake of news of an order from France-based renewable green hydrogen provider Lhyfe S.A. of proton exchange membrane (PEM) electrolyzers with a total capacity of 50 megawatts (MW), or up to 20 tons per day. With the order of 10, 5 MW PEM electrolyzer systems, Lhyfe is looking to produce renewable green hydrogen using primarily wind and solar power for mobility applications, such as forklifts and light commercial vehicles
The iPhone 14 arrives during a tough climate for the U.S. wireless market, but a Verizon Communications Inc. executive is upbeat about the efforts her company has taken both before and in response to Apple Inc.'s big launch.
General Motors wants to take Chinese market share from its local competitors. The company will launch a direct-to-consumer selling model in China, according to a report by Reuters. GM (ticker: GM) didn’t immediately respond to a request for comment from Barron’s.
Gold futures ended lower on Thursday, pressured by remarks from Federal Reserve Chairman Jerome Powell that implied the central bank will continue to boost interest rate as it attempts to bring down inflation. U.S. initial jobless claims fell last week to a three-and-a-half-month low, "underscoring a robust jobs market even as the Fed launches monetary bazookas," said Lukman Otunuga, manager, market analysis, at FXTM. "This is likely to fuel speculation around more aggressive rate hikes -- ultim
Snap Inc.'s stock was powering toward another session of strong gains Thursday in the wake of Chief Executive Evan Spiegel's presentation at a conference as well as some upbeat analyst commentary about the social-media company's internal targets and the state of the advertising market.
Mercer International (MERC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
(Bloomberg) -- Citadel Securities, one of the finance industry’s biggest market makers, said that lowering the minimum price increment at which a security gets traded to less than a penny across all stocks could have a negative impact on markets.Most Read from BloombergCharles Becomes King as the Face of a Nation ChangesDouble Rainbow Appears Over Buckingham Palace as Crowd Gathers to Mourn QueenQueen Elizabeth’s Doctors Are Concerned for Her HealthQueen Elizabeth II, Britain’s Longest-Reigning
The European Central Bank raised its key interest rates by an unprecedented 75 basis points on Thursday and promised further hikes, prioritising the fight against inflation even as the bloc is likely heading towards a winter recession and gas rationing. With inflation at a half-century high and approaching double-digit territory, policymakers are worried that rapid price growth is getting entrenched, melting away household savings, thwarting investment and setting off a hard-to-break wage-price spiral. Following up on a large July rate hike, the ECB raised its deposit rate to 0.75% from zero and lifted its main refinancing rate to 1.25%, the highest level for both since 2011, with moves promised for the next several meetings.
It’s good news for South Africa’s economy that the banking and insurance sectors are growing, but bad news that the risk of cybercrime is on the rise including on financial services apps.
Amazon's Buy With Prime program could boost its e-commerce dominance. But Google has refocused on using e-commerce-related searches to boost advertising growth.
CIEN, CYH and ICUI have been added to the Zacks Rank #5 (Strong Sell) List on September 8, 2022.
Just as the yen's eye-popping plunge against the dollar grabs the world's financial market spotlight, investors will get a closer look on Thursday into the underlying state of the Japanese economy. Revised second quarter GDP data, and trade and current account figures for July, will give an insight into the yen's economic fundamentals, and offer clues to whether the level and pace of the currency's depreciation are justified. Economists expected Japan's Q2 GDP growth to be revised up to an annualised 2.9% rate from 2.2%, and quarterly growth to be revised up to 0.7% from 0.5%.
Investor-friendly steps as well as a large and diverse addressable market boost Gartner (IT) stock.
The White House Office of Science and Technology Policy called for further research on the energy impact of crypto mining to set standards for the industry. The European Central Bank (ECB) raised interest rates by 0.75 percentage points Thursday, the biggest single hike since it began setting monetary policy in 1999. SEC Chairman Gary Gensler speaks to CoinDesk on the state of crypto regulation.
Pacira (PCRX) reports encouraging top-line data from the phase III study evaluating Exparel as a single-dose femoral nerve block in the adductor canal for total knee arthroplasty. Shares rise.